Ovarian Cancer Opportunity Assessment and Forecast Report 2024: Sales of ImmunoGen's Elahere Represent the Most Impactful Driver of Growth - ResearchAndMarkets.com
This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer.
- This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 7MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for Ovarian Cancer.
- Ovarian cancer patients generally respond well to platinum-based chemotherapy and achieve complete remission in the initial setting.
- Major drivers of growth in the Ovarian Cancer market across the 7MM over the forecast period include the following:
The sales of ImmunoGen's Elahere represent the most impactful driver of growth for the ovarian cancer market. - Voluntary withdrawals and generic erosion upon the patent expiries of the PARP inhibitors will temper sales growth during the forecast period in the ovarian cancer market.